The Belgian biotech company Galapagos has announced the closure of its cell therapy division, a move that jeopardizes the future of its Leiden site, historically a pivotal hub for cell therapy research and development. This decision will impact approximately 365 employees globally, including a significant number in the Netherlands, as reported by NU.nl.
CEO Henry Gosebruch characterized the decision as challenging yet essential, emphasizing the company”s intention to concentrate its resources on developing “new medicines that are truly needed.” The Leiden facility has been instrumental in the creation of innovative gene therapies targeting diseases with limited treatment options.
The shutdown of the cell therapy division raises concerns not only for the Leiden location but also for facilities in Basel, Switzerland, Shanghai, China, and the United States. According to Galapagos, this action follows a comprehensive strategic review aimed at reallocating funds to more promising research initiatives.
Initially, the company explored the possibility of spinning off its cell therapy division but was unable to identify a viable buyer or investor for the operation. This outcome reflects the increasing challenges faced by biotech firms in securing investments for specialized divisions, particularly in the rapidly evolving field of cell therapy.
